“`html
The average one-year price target for Pharvaris N.V. (NasdaqGS:PHVS) has risen to $45.73 per share, a 20.90% increase from the previous estimate of $37.82 made on November 14, 2025. Currently, the price target ranges from a low of $30.30 to a high of $80.85 per share, representing a potential increase of 72.31% from the latest closing price of $26.54 per share.
Currently, 115 funds and institutions hold positions in Pharvaris, up 29.21% from the last quarter. Total shares owned by these institutions increased by 28.49% to 58,210K shares, with an average portfolio weight of 1.67%, an increase of 13.25%. The put/call ratio stands at 0.93, indicating a bullish outlook.
General Atlantic holds 12.36% ownership with 8,031K shares, having increased its stake by 6.23%. Foresite Capital Management Iv holds 7.36% with 4,779K shares, a 7.70% increase. venBio Partners and Viking Global Investors hold 7.14% and 5.62% ownership respectively, with venBio decreasing its allocation by 0.25% last quarter.
“`
